NEW YORK, NY / ACCESSWIRE / September 7, 2017 / After posting the worst daily drop in weeks on rising geopolitical tensions between North Korea and the from their worst daily drop in weeks, U.S. markets rebounded Wednesday. The Dow Jones Industrial Average gained 0.25 percent to close at 21,807.64, while the S&P 500 Index increased 0.31 percent to close at 2,465.54. The NASDAQ Composite Index rose 0.28 percent to close at 6,393.31. Major indexes rallied Wednesday as President Donald Trump and congressional leaders agreed to extend the debt ceiling and fund the government for an additional three months.

"While the [market] outlook is generally positive, there are a lot of risk factors out there," said Richard Benson, co-head of portfolio investments at Millennium Global Investments. "I'm positive but worried."

RDI Initiates Coverage on:

Athersys, Inc.
https://rdinvesting.com/news/?ticker=ATHX

Catalyst Biosciences Inc.
https://rdinvesting.com/news/?ticker=CBIO

Athersys Inc.'s stock jumped 10.22% Wednesday, to close the day at $2.05. The stock recorded a trading volume of 3,275,637 shares, which was above its three months average volume of 686,764 shares. In the last year, Athersys Inc.'s shares have traded in a range of 1.02 - 2.30. The share price has gained 100.98% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $1.62 is greater than its 200-day moving average of $1.48. Shares of Athersys have gained approximately 33.99 percent year-to-date.

Access RDI's Athersys, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ATHX

On Wednesday, shares of Catalyst Biosciences Inc. recorded a trading volume of 8,723,574 shares, which was above the three months average volume of 145,834 shares. The stock ended the day 11.50% higher at 3.78. The share price has gained 21.54% from its 52 week low with a 52 week trading range of 3.11 - 21.30.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $3.71 is below its 200-day moving average of $4.89. Shares of Catalyst Biosciences have fallen approximately 61.04 percent year-to-date.

Access RDI's Catalyst Biosciences Inc. Research Report at:
https://rdinvesting.com/news/?ticker=CBIO

Our Actionable Research on Athersys, Inc. (NASDAQ:ATHX) and Catalyst Biosciences Inc. (NASDAQ:CBIO) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com